FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:MAPK14-EHMT1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: MAPK14-EHMT1
FusionPDB ID: 51517
FusionGDB2.0 ID: 51517
HgeneTgene
Gene symbol

MAPK14

EHMT1

Gene ID

1432

79813

Gene namemitogen-activated protein kinase 14euchromatic histone lysine methyltransferase 1
SynonymsCSBP|CSBP1|CSBP2|CSPB1|EXIP|Mxi2|PRKM14|PRKM15|RK|SAPK2A|p38|p38ALPHAEHMT1-IT1|EUHMTASE1|Eu-HMTase1|FP13812|GLP|GLP1|KLEFS1|KMT1D
Cytomap

6p21.31

9q34.3

Type of geneprotein-codingprotein-coding
Descriptionmitogen-activated protein kinase 14CSAID-binding proteinMAP kinase 14MAP kinase Mxi2MAP kinase p38 alphaMAX-interacting protein 2cytokine suppressive anti-inflammatory drug binding proteinmitogen-activated protein kinase p38 alphap38 MAP kinasep3histone-lysine N-methyltransferase EHMT1EHMT1 intronic transcript 1G9a-like protein 1H3-K9-HMTase 5euchromatic histone-lysine N-methyltransferase 1histone H3-K9 methyltransferase 5histone-lysine N-methyltransferase, H3 lysine-9 specific 5lysine N-m
Modification date2020032920200313
UniProtAcc

Q16539

Main function of 5'-partner protein: FUNCTION: Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK14 is one of the four p38 MAPKs which play an important role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical stress leading to direct activation of transcription factors. Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. Some of the targets are downstream kinases which are activated through phosphorylation and further phosphorylate additional targets. RPS6KA5/MSK1 and RPS6KA4/MSK2 can directly phosphorylate and activate transcription factors such as CREB1, ATF1, the NF-kappa-B isoform RELA/NFKB3, STAT1 and STAT3, but can also phosphorylate histone H3 and the nucleosomal protein HMGN1. RPS6KA5/MSK1 and RPS6KA4/MSK2 play important roles in the rapid induction of immediate-early genes in response to stress or mitogenic stimuli, either by inducing chromatin remodeling or by recruiting the transcription machinery. On the other hand, two other kinase targets, MAPKAPK2/MK2 and MAPKAPK3/MK3, participate in the control of gene expression mostly at the post-transcriptional level, by phosphorylating ZFP36 (tristetraprolin) and ELAVL1, and by regulating EEF2K, which is important for the elongation of mRNA during translation. MKNK1/MNK1 and MKNK2/MNK2, two other kinases activated by p38 MAPKs, regulate protein synthesis by phosphorylating the initiation factor EIF4E2. MAPK14 interacts also with casein kinase II, leading to its activation through autophosphorylation and further phosphorylation of TP53/p53. In the cytoplasm, the p38 MAPK pathway is an important regulator of protein turnover. For example, CFLAR is an inhibitor of TNF-induced apoptosis whose proteasome-mediated degradation is regulated by p38 MAPK phosphorylation. In a similar way, MAPK14 phosphorylates the ubiquitin ligase SIAH2, regulating its activity towards EGLN3. MAPK14 may also inhibit the lysosomal degradation pathway of autophagy by interfering with the intracellular trafficking of the transmembrane protein ATG9. Another function of MAPK14 is to regulate the endocytosis of membrane receptors by different mechanisms that impinge on the small GTPase RAB5A. In addition, clathrin-mediated EGFR internalization induced by inflammatory cytokines and UV irradiation depends on MAPK14-mediated phosphorylation of EGFR itself as well as of RAB5A effectors. Ectodomain shedding of transmembrane proteins is regulated by p38 MAPKs as well. In response to inflammatory stimuli, p38 MAPKs phosphorylate the membrane-associated metalloprotease ADAM17. Such phosphorylation is required for ADAM17-mediated ectodomain shedding of TGF-alpha family ligands, which results in the activation of EGFR signaling and cell proliferation. Another p38 MAPK substrate is FGFR1. FGFR1 can be translocated from the extracellular space into the cytosol and nucleus of target cells, and regulates processes such as rRNA synthesis and cell growth. FGFR1 translocation requires p38 MAPK activation. In the nucleus, many transcription factors are phosphorylated and activated by p38 MAPKs in response to different stimuli. Classical examples include ATF1, ATF2, ATF6, ELK1, PTPRH, DDIT3, TP53/p53 and MEF2C and MEF2A. The p38 MAPKs are emerging as important modulators of gene expression by regulating chromatin modifiers and remodelers. The promoters of several genes involved in the inflammatory response, such as IL6, IL8 and IL12B, display a p38 MAPK-dependent enrichment of histone H3 phosphorylation on 'Ser-10' (H3S10ph) in LPS-stimulated myeloid cells. This phosphorylation enhances the accessibility of the cryptic NF-kappa-B-binding sites marking promoters for increased NF-kappa-B recruitment. Phosphorylates CDC25B and CDC25C which is required for binding to 14-3-3 proteins and leads to initiation of a G2 delay after ultraviolet radiation. Phosphorylates TIAR following DNA damage, releasing TIAR from GADD45A mRNA and preventing mRNA degradation. The p38 MAPKs may also have kinase-independent roles, which are thought to be due to the binding to targets in the absence of phosphorylation. Protein O-Glc-N-acylation catalyzed by the OGT is regulated by MAPK14, and, although OGT does not seem to be phosphorylated by MAPK14, their interaction increases upon MAPK14 activation induced by glucose deprivation. This interaction may regulate OGT activity by recruiting it to specific targets such as neurofilament H, stimulating its O-Glc-N-acylation. Required in mid-fetal development for the growth of embryo-derived blood vessels in the labyrinth layer of the placenta. Also plays an essential role in developmental and stress-induced erythropoiesis, through regulation of EPO gene expression. Isoform MXI2 activation is stimulated by mitogens and oxidative stress and only poorly phosphorylates ELK1 and ATF2. Isoform EXIP may play a role in the early onset of apoptosis. Phosphorylates S100A9 at 'Thr-113'. {ECO:0000269|PubMed:10330143, ECO:0000269|PubMed:10747897, ECO:0000269|PubMed:10943842, ECO:0000269|PubMed:11154262, ECO:0000269|PubMed:11333986, ECO:0000269|PubMed:15905572, ECO:0000269|PubMed:16932740, ECO:0000269|PubMed:17003045, ECO:0000269|PubMed:17724032, ECO:0000269|PubMed:19893488, ECO:0000269|PubMed:20188673, ECO:0000269|PubMed:20932473, ECO:0000269|PubMed:9430721, ECO:0000269|PubMed:9687510, ECO:0000269|PubMed:9792677, ECO:0000269|PubMed:9858528}.; FUNCTION: (Microbial infection) Activated by phosphorylation by M.tuberculosis EsxA in T-cells leading to inhibition of IFN-gamma production; phosphorylation is apparent within 15 minute and is inhibited by kinase-specific inhibitors SB203580 and siRNA (PubMed:21586573). {ECO:0000269|PubMed:21586573}.

Q9H9B1

Main function of 5'-partner protein: FUNCTION: Histone methyltransferase that specifically mono- and dimethylates 'Lys-9' of histone H3 (H3K9me1 and H3K9me2, respectively) in euchromatin. H3K9me represents a specific tag for epigenetic transcriptional repression by recruiting HP1 proteins to methylated histones. Also weakly methylates 'Lys-27' of histone H3 (H3K27me). Also required for DNA methylation, the histone methyltransferase activity is not required for DNA methylation, suggesting that these 2 activities function independently. Probably targeted to histone H3 by different DNA-binding proteins like E2F6, MGA, MAX and/or DP1. During G0 phase, it probably contributes to silencing of MYC- and E2F-responsive genes, suggesting a role in G0/G1 transition in cell cycle. In addition to the histone methyltransferase activity, also methylates non-histone proteins: mediates dimethylation of 'Lys-373' of p53/TP53. Represses the expression of mitochondrial function-related genes, perhaps by occupying their promoter regions, working in concert with probable chromatin reader BAZ2B (By similarity). {ECO:0000250|UniProtKB:Q5DW34, ECO:0000269|PubMed:12004135, ECO:0000269|PubMed:20118233}.
Ensembl transtripts involved in fusion geneENST idsENST00000229794, ENST00000310795, 
ENST00000468133, ENST00000229795, 
ENST00000334856, ENST00000460843, 
ENST00000371394, ENST00000462484, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score7 X 6 X 5=21015 X 14 X 10=2100
# samples 721
** MAII scorelog2(7/210*10)=-1.58496250072116
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(21/2100*10)=-3.32192809488736
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: MAPK14 [Title/Abstract] AND EHMT1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: MAPK14 [Title/Abstract] AND EHMT1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)MAPK14(36063843)-EHMT1(140605419), # samples:1
Anticipated loss of major functional domain due to fusion event.MAPK14-EHMT1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
MAPK14-EHMT1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
MAPK14-EHMT1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
MAPK14-EHMT1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneMAPK14

GO:0035556

intracellular signal transduction

10838079

HgeneMAPK14

GO:0071222

cellular response to lipopolysaccharide

23776175

HgeneMAPK14

GO:1900015

regulation of cytokine production involved in inflammatory response

15251176

TgeneEHMT1

GO:0006325

chromatin organization

12004135

TgeneEHMT1

GO:0016571

histone methylation

12004135

TgeneEHMT1

GO:0018027

peptidyl-lysine dimethylation

20118233



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr6:36063843/chr9:140605419)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across MAPK14 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across EHMT1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000229794MAPK14chr636063843-ENST00000462484EHMT1chr9140605419+3799115016335551130
ENST00000468133MAPK14chr636063843-ENST00000462484EHMT1chr9140605419+348183210632371043
ENST00000310795MAPK14chr636063843-ENST00000462484EHMT1chr9140605419+3411762031671055

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000229794ENST00000462484MAPK14chr636063843-EHMT1chr9140605419+0.003291770.99670815
ENST00000468133ENST00000462484MAPK14chr636063843-EHMT1chr9140605419+0.0032910570.99670887
ENST00000310795ENST00000462484MAPK14chr636063843-EHMT1chr9140605419+0.0022035040.99779654

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for MAPK14-EHMT1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
MAPK14chr636063843EHMT1chr91406054191150329PGAELLKKISSESAVPARGEPQQDCC
MAPK14chr636063843EHMT1chr9140605419762254PGAELLKKISSESAVPARGEPQQDCC
MAPK14chr636063843EHMT1chr9140605419832242PGAELLKKISSESAVPARGEPQQDCC

Top

Potential FusionNeoAntigen Information of MAPK14-EHMT1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Potential FusionNeoAntigen Information of MAPK14-EHMT1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
MAPK14-EHMT1_36063843_140605419.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0101LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0101LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0101KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0102LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0102LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0102KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0102ELLKKISSESAVPAR318
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0103LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0105LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0105LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0105KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0107LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0107LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0107KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0109LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0109LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0109KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0111LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0111LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0111KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0113LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0113LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0113KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0115LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0115LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0115KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0117LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0117LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0117KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0119LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0119LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0119KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0121LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0121LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0121KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0123LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0123LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0123KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0123ELLKKISSESAVPAR318
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0125LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0125LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0125KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0127LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0127LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0127KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0129LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0129LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0129KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0131LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0131LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0131KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0413LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0413LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0413AELLKKISSESAVPA217
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0422LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0422LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0427AELLKKISSESAVPA217
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0437GAELLKKISSESAVP116
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0440LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0440AELLKKISSESAVPA217
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0444LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0444LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0444AELLKKISSESAVPA217
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0444KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0455LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0456AELLKKISSESAVPA217
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0464LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0468LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0468AELLKKISSESAVPA217
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0470LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0472LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0478AELLKKISSESAVPA217
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0479LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-0479AELLKKISSESAVPA217
MAPK14-EHMT1chr636063843chr91406054191150DRB1-1001LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-1002LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-1002LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-1002KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB1-1002ELLKKISSESAVPAR318
MAPK14-EHMT1chr636063843chr91406054191150DRB1-1003LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-1525LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB1-1525LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB1-1615AELLKKISSESAVPA217
MAPK14-EHMT1chr636063843chr91406054191150DRB3-0201LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB3-0204LKKISSESAVPARGE520
MAPK14-EHMT1chr636063843chr91406054191150DRB3-0204LLKKISSESAVPARG419
MAPK14-EHMT1chr636063843chr91406054191150DRB3-0204KKISSESAVPARGEP621
MAPK14-EHMT1chr636063843chr91406054191150DRB3-0224LKKISSESAVPARGE520

Top

Fusion breakpoint peptide structures of MAPK14-EHMT1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of MAPK14-EHMT1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score

Top

Vaccine Design for the FusionNeoAntigens of MAPK14-EHMT1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
MAPK14-EHMT1chr636063843chr9140605419116GAELLKKISSESAVPGGGGCTGAGCTTTTGAAGAAAATCTCCTCAGAGTCTGCAGTTCCG
MAPK14-EHMT1chr636063843chr9140605419217AELLKKISSESAVPAGCTGAGCTTTTGAAGAAAATCTCCTCAGAGTCTGCAGTTCCGGCG
MAPK14-EHMT1chr636063843chr9140605419318ELLKKISSESAVPARGAGCTTTTGAAGAAAATCTCCTCAGAGTCTGCAGTTCCGGCGAGG
MAPK14-EHMT1chr636063843chr9140605419419LLKKISSESAVPARGCTTTTGAAGAAAATCTCCTCAGAGTCTGCAGTTCCGGCGAGGGGG
MAPK14-EHMT1chr636063843chr9140605419520LKKISSESAVPARGETTGAAGAAAATCTCCTCAGAGTCTGCAGTTCCGGCGAGGGGGGAG
MAPK14-EHMT1chr636063843chr9140605419621KKISSESAVPARGEPAAGAAAATCTCCTCAGAGTCTGCAGTTCCGGCGAGGGGGGAGCCT

Top

Information of the samples that have these potential fusion neoantigens of MAPK14-EHMT1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample

Top

Potential target of CAR-T therapy development for MAPK14-EHMT1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to MAPK14-EHMT1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to MAPK14-EHMT1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource